No Data
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $20
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate
Vanda Pharmaceuticals' New Drug Application Accepted by FDA
Insider Purchase: President and CEO of $VNDA Buys 10,000 Shares
Express News | Vanda Pharmaceuticals Announces the Publication of an Article Titled "Potential Aso-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S"
Vanda Pharmaceuticals Announces the Publication of an Article Titled "Potential ASO-based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S"
